Unified Signal, Inc. announced that it has entered into an exclusive agreement with Pharmazam to launch a suit of on-demand wellness services using DNA analysis and testing. The product will have 5 available modules including; ancestry information, metabolism analysis, disease screening, drug to gene interactions, and an optional allergen test. The collaboration will allow customers to screen over 18,000 approved prescribed and OTC drugs to determine what the likelihood is of how customers will respond to those drugs. Pharmazam’s personalized medication management system instantly checks drug to drug, drug to gene, drug to illness, drug to allergy, and drug to lifestyle and then compares that information to the person’s personalized healthcare profile so that the absolute best medication choice can be made. Unified Signal and Pharmazam through its partnership, will also be adding genetic disease screening for more than 3,400 diseases, ancestry type analysis, and telemedicine services to the product portfolio. The new on-demand wellness service which is being secured in Unified Signal’s crypto-wallet, can be purchased by consumers and for a small monthly recurring fee, they will receive real-time updates as new medications enter the marketplace and as breakthroughs occur each month in the disease diagnostic arena. This deal comes on the heels of the much anticipated crypto-wallet scope expansion, which now will house crypto-currency as well as healthcare and wellness data. Unified Signal is on track to deploy the new crypt-wallet as well as the heath wallet and wellness services in first quarter of 2018. Unified Signal’s partnership with BurstIQ and their HIPPA-compliant blockchain platform will ensure that customer data is completely secure within the new crypto-wallet product suite.